New research published in JAMA Neurology highlights disparities in migraine based on sexual orientation in the United States.
New research published in JAMA Neurology highlights disparities in migraine based on sexual orientation in the United States.
Disparities in migraine prevalence based on race/ethnicity, sex, and socioeconomic status have previously been established. However, there is a lack of research on disparities based on sexual orientation, researchers said.
“Sexual minority groups (eg, lesbian, gay, bisexual, and other nonheterosexual people) may experience unique discrimination, stigma, and barriers to health care access, thus leading to disparities in physical and mental health,” authors wrote.
To better understand the relationship between sexual orientation and migraine, researchers analyzed data from Wave V of the National Longitudinal Study of Adolescent to Adult Health. The cross-sectional, nationally representative sample consisted of adults aged 31 to 42 and data analysis took place between May 2020 and June 2020.
The sample consisted of 9894 adults with a mean age of 37.33. Migraine was determined based on self-reported responses to an interview question consistent with the International Classification of Headache Disorders diagnostic criteria for migraine without aura: “Have you ever had five or more headaches that were at least four hours long; one-sided, pulsating, intense, or worsened by activity; and associated with nausea, vomiting, or sensitivity to light or sound?”
Participants were classified into 3 groups: exclusively heterosexual; mostly heterosexual but somewhat attracted to people of one’s own sex; or lesbian, gay, or bisexual.
Fifty-one percent (n = 5705) of the sample were women and the majority (n = 8426 [85.8%]) identified as exclusively heterosexual. Ten percent (n = 1062) identified as mostly heterosexual while 4.2% (n = 406) identified as lesbian, gay, or bisexual.
Researchers found:
Previous research has also shown a high prevalence of migraine and other physical health outcomes among adults in sexual minority groups in California, but the current study is the first to the authors’ knowledge to reveal theses disparities among a nationally representative sample.
Authors hypothesize the combination of prejudice, stigma, and discrimination, defined as sexual minority stress, may contribute to increased odds of experiencing migraine in this cohort. Members of sexual minority groups can also encounter barriers to health care and may experience greater mental and physical health problems compared with the general population.
Due to limited power, researchers were unable to analyze the association of migraine prevalence with specific sexual orientations (lesbian, gay, bisexual), marking a limitation to the study. Additional limitations include self-reported measures and inability to differentiate sexual identity from behavior.
“Clinicians and researchers should be aware of health disparities in migraine, including sexual orientation, in addition to biological and behavioral risk factors,” authors concluded.
Reference
Nagata JM, Ganson KT, Tabler J, Blashill AJ, Murray SB. Disparities across sexual orientation in migraine among US adults. JAMA Neurol. Published online September 28, 2020. doi:10.1001/jamaneurol.2020.3406
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen